The New York State Health Department has warned that it does not have enough Paxlovid or Molnupiravir antibody treatment and authorized those of non-white race or Hispanic/Latino ethnicity, as well as individuals with underlying medical conditions that increase their risk for severe illness, to receive the treatment. However, the government body made no mention of whether or not other race categories should apply to receive the drugs. In a notification (pdf) issued on Dec. 27, the department warned there is currently a shortage of Paxlovid, a Pfizer oral COVID-19 antiviral pill, which has been authorized for emergency use by the U.S. Food and Drug Administration. Paxlovid is taken twice per day for five days in combination with a second medicine called ritonavir, a generic antiviral drug. The drug is aimed to help patients who are suffering from “mild-to-moderate” COVID-19 symptoms from becoming so sick that they need to be hospitalized, Pfizer has said. Stocks of Molnupiravir antibody treatment, a …
RSS Feed | The Epoch Times